Management of Difficult Cases of Autoimmune Hepatitis
详细信息    查看全文
European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004. Electronic address: easloffice@easloffice.eu. Most up to date, recently released national society AIH consensus statement aimed at providing diagnostic and therapeutic guidance for clinicians. Includes a wide collection of small observational AIH studies, few randomized controlled trails, and a large degree of expert opinion.CrossRef
2.Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet. 2013;382(9902):1433–44.PubMed CrossRef
3.Waldenstrom J. Liver, blood proteins and nutritive protein. Dtsch Z Für Verdau- Stoffwechselkrankheiten. 1953;9:113–9.
4.de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21(6):1956–71.PubMed PubMedCentral CrossRef
5.Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144(3):560–9.e7. quiz e13–4.PubMed CrossRef
6.Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46(6):1828–35.PubMed CrossRef
7.•
Ngu JH, Gearry RB, Frampton CM, Stedman CAM. Predictors of poor outcome in patients with autoimmune hepatitis: a population-based study. Hepatology. 2013;57(6):2399–406. A large population based evaluation of 133 AIH patients and predictors of outcome with median follow-up of 9 years. Model indicated that early normalization of liver tests are associated with improved outcomes, yet cirrhosis, was not a poor predictor.PubMed CrossRef
8.•
Kirstein MM, Metzler F, Geiger E, Heinrich E, Hallensleben M, Manns MP, et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology. 2015;62(5):1524–35. A large European single center outcome experience with 354 AIH patients. Early diagnosis (<18 years) and + anti-SLA/LP antibodies were significant risk factors for worse outcomes.PubMed CrossRef
9.Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42(1):53–62.PubMed CrossRef
10.Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40(158):159–85.PubMed CrossRef
11.••
Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014;60(3):612–7. A Danish nationwide assessment of over 1700 AIH patients indicating that AIH incidence doubled during the study period (1994–2012). During the first year of AIH diagnosis, mortality was 6 times higher than that of the general population, and 2 times higher thereafter.PubMed CrossRef
12.Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213.PubMed CrossRef
13.•Hübener S, Oo YH, Than NN, Hübener P, Weiler-Normann C, Lohse AW, et al. Efficacy of 6-Mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol. 2015. doi:10.​1016/​j.​cgh.​2015.​09.​037 . Largest assessment of 6-MP in AIH patients that are intolerant to AZA therapy. 75% (15) of patients tolerated 6-MP well even after significant (mostly gastrointestinal) side effects of AZA.PubMed
14.Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46(4):1138–45.PubMed CrossRef
15.Werner M, Wallerstedt S, Lindgren S, Almer S, Björnsson E, Bergquist A, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol. 2010;45(4):457–67.PubMed CrossRef
16.Lüth S, Herkel J, Kanzler S, Frenzel C, Galle PR, Dienes HP, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 2008;42(8):926–30.PubMed CrossRef
17.Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103(12):3063–70.PubMed CrossRef
18.•Jothimani D, Cramp ME, Cross TJS. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis—an observational study. J Clin Exp Hepatol. 2014;4(3):221–5. MMF is well tolerated in 74% of AIH patients with AZA intolerance. In a small subgroup, it is unlikely to provide liver test normalization in AZA treatment failure.PubMed PubMedCentral CrossRef
19.Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott IDR. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27(3):220–7.PubMed CrossRef
20.Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SHC. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29(6):654–61.PubMed CrossRef
21.Czaja AJ. Drug choices in autoimmune hepatitis: part a—steroids. Expert Rev Gastroenterol Hepatol. 2012;6(5):603–15.PubMed CrossRef
22.Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnićk GL, Elveback IR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63(5):820–33.PubMed
23.Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198–206.PubMed CrossRef
24.Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2006;24(8):1197–205.PubMed CrossRef
25.Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004;99(8):1510–6.PubMed CrossRef
26.Muratori L, Muratori P, Lanzoni G, Ferri S, Lenzi M. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology. 2010;52(5):1857.PubMed CrossRef
27.Kanzler S, Löhr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Für Gastroenterol. 2001;39(5):339–48.CrossRef
28.•Dhaliwal HK, Hoeroldt BS, Dube AK, McFarlane E, Underwood JCE, Karajeh MA, et al. Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol. 2015;110(7):993–9. A small paired liver biopsy study revealing that only young age at diagnosis and continued disease activity on biopsy (despite normal liver tests) are associated with reduced transplant-free survival.PubMed CrossRef
29.•van Gerven NMF, Verwer BJ, Witte BI, van Erpecum KJ, van Buuren HR, Maijers I, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014;49(10):1245–54. This large Scandinavian AIH epidemiology study revealed AIH prevalence is 18.3 per 100,000 and concurrent autoimmune diseases were found in a quarter of those with AIH.PubMed CrossRef
30.Sockalingam S, Blank D, Abdelhamid N, Abbey SE, Hirschfield GM. Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. J Hepatol. 2012;57(6):1299–304.PubMed CrossRef
31.Dhaliwal HK, Anderson R, Thornhill EL, Schneider S, McFarlane E, Gleeson D, et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology. 2012;56(4):1401–8.PubMed CrossRef
32.Ansari A, Elliott T, Baburajan B, Mayhead P, O’Donohue J, Chocair P, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(6):734–41.PubMed CrossRef
33.Al-Shamma S, Eross B, Mclaughlin S. Use of a xanthine oxidase inhibitor in autoimmune hepatitis. Hepatology. 2013;57(3):1281–2.PubMed CrossRef
34.Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24(10):588–92.PubMed PubMedCentral
35.Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol. 2011;55(3):636–46.PubMed CrossRef
36.Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A(3):588–96.PubMed CrossRef
37.Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant. 2005;5(5):1085–9.PubMed CrossRef
38.Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med. 2014;127(11):1128–31.PubMed CrossRef
39.Ytting H, Larsen FS. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol. 2015;50(8):1025–31.PubMed CrossRef
40.Porcelli L, Quatrale AE, Mantuano P, Silvestris N, Rolland JF, Biancolillo L, et al. Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors. Curr Pharm Des. 2013;19(5):918–26.PubMed CrossRef
41.Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther. 2013;38(4):343–64.PubMed CrossRef
42.Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94(1):241–8.PubMed CrossRef
43.Tannous MM, Cheng J, Muniyappa K, Farooq I, Bharara A, Kappus M, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34(3):405–7.PubMed CrossRef
44.Ichai P, Duclos-Vallée J-C, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13(7):996–1003.PubMed CrossRef
45.Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther. 2006;23(9):1347–53.PubMed CrossRef
46.•Yeoman AD, Westbrook RH, Zen Y, Bernal W, Al-Chalabi T, Wendon JA, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol. 2014;61(4):876–82. Well phenotyped, acute severe hepatitis carries a high risk of progression to transplant or death. Treatment with high-dose corticosteroids did not increase risk for poor outcomes. Approximately half of patients treated with steroids recovered, yet there was no difference in MELD scores for responders versus nonresponders in this group.PubMed CrossRef
47.De Martin E, Coilly A, Ichai P, Samuel D, Duclos-Vallée J-C. The role of corticosteroids in acute-severe autoimmune hepatitis is still highly debatable. J Hepatol. 2015;63(4):1041–2.PubMed CrossRef
48.••Mendizabal M, Marciano S, Videla MG, Anders M, Zerega A, Balderramo DC, et al. Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure. Eur J Gastroenterol Hepatol. 2015;27(6):644–8. Approximately half of fulminant AIH patients are rescued from transplant with corticosteroids. Advanced hepatic encephalopathy and a higher MELD (>27) score seemed to be associated with corticosteroid failure.PubMed
49.Westbrook RH, Yeoman AD, Kriese S, Heneghan MA. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun. 2012;38(2–3):J239–44.PubMed CrossRef
50.Werner M, Björnsson E, Prytz H, Lindgren S, Almer S, Broomé U, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol. 2007;42(8):986–91.PubMed CrossRef
51.Heneghan MA, Norris SM, O’Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut. 2001;48(1):97–102.PubMed PubMedCentral CrossRef
52.Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol. 2006;101(3):556–60.PubMed CrossRef
53.Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124(1):9–17.PubMed CrossRef
54.Christopher V, Al-Chalabi T, Richardson PD, Muiesan P, Rela M, Heaton ND, et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl. 2006;12(7):1138–43.PubMed CrossRef
55.Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science. 1999;283(5406):1277–8.PubMed CrossRef
56.Kim M, Rostas S, Gabardi S. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant. 2013;13(6):1383–9.PubMed CrossRef
57.Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol. 2002;35(1):75–81.PubMed CrossRef
58.Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol. 1993;18(1):15–23.PubMed CrossRef
59.Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40(4):646–52.PubMed CrossRef
60.Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29(6):816–23.PubMed CrossRef
61.Chen J, Eslick GD, Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther. 2014;39(2):117–24.PubMed CrossRef
62.Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110(3):848–57.PubMed CrossRef
63.Uribe M, Go VL, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol. 1984;6(4):331–5.PubMed
64.Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci. 2012;57(9):2248–66.PubMed CrossRef
65.Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 2002;8(6):505–13.PubMed CrossRef
66.González-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001;7(4):302–10.PubMed CrossRef
67.Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology. 2000;32(2):185–92.PubMed CrossRef
68.Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15(10):1254–61.PubMed CrossRef
69.Duclos-Vallee J-C, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15 Suppl 2:S25–34.PubMed CrossRef
70.Tencate V, Komorowski R, Cronin D, Hong J, Gawrieh S. A case study: refractory recurrent autoimmune hepatitis following liver transplantation in two male patients. Transplant Proc. 2014;46(1):298–300.PubMed CrossRef
71.•Lammert C, Comerford M, Love J, Bailey JR. Investigation gone viral: application of the social mediasphere in research. Gastroenterology. 2015;149(4):839–43. The rarity of AIH and challenge of geographic barriers represent major limitations to development of large observational and prospective studies. Social media overcomes these limitations, and provides patient access to support and disease engagement.PubMed CrossRef
  • 作者单位：Craig Lammert (1)
    Veronica M. Loy (2)
    Kiyoko Oshima (3)
    Samer Gawrieh (1)

    1. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 702 Rotary Circle, Suite 225, Indianapolis, IN, 46202, USA
    2. Division of Hepatology, Loyola University, Maywood, IL, USA
    3. Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
  • 刊物主题：Gastroenterology;
  • 出版者：Springer US
  • ISSN：1534-312X
    • 文摘
    Autoimmune hepatitis (AIH) is a complex autoimmune disease characterized by immune-mediated destruction of hepatic parenchyma which can result in cirrhosis, liver failure, and death. Current American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of Liver (EASL) guidelines recommend corticosteroids alone or in combination with azathioprine as first-line treatment strategies. However, a significant proportion of patients may not be able to tolerate or achieve complete biochemical response with these options. In this article, we discuss approaches to these patients and other challenging AIH patient groups such as the asymptomatic, pregnant, elderly, and liver transplant recipients. Keywords Autoimmune hepatitis Pregnancy Cirrhosis Nonstandard treatment Liver transplantation Refractory

    © 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

    地址：北京市海淀区学院路29号 邮编：100083

    电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700